ArticleRadiation oncology (London, England)2025
Dose-dependent taste dysfunction in head and neck cancer patients receiving radiotherapy.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThis study aimed to investigate the progression of taste dysfunction (TD) in patients with head and neck cancer (HNC) receiving radiotherapy (RT) and to develop a normal tissue complication probability (NTCP) model for predicting TD.
methodsA cross-sectional study was conducted on August 23rd and 24th, 2023. Eligible participants included newly diagnosed, pathologically confirmed HNC patients without distant metastasis. Acute toxicities were assessed via the NCI CTCAE v5.0, and taste acuity was evaluated via the Subjective Total Taste Acuity (STTA) Scale. Radiation dose data for organs at risk (OARs) were collected. Descriptive statistics and multivariate logistic regression were employed to develop the NTCP models.
resultsAmong the 444 participants, 265 (60%) experienced TD with a CTCAE grade ≥ 2. Acute TD was significantly associated with body mass index (BMI) (OR: 0.936, P = 0.029). The mean dose (Dmean) of the parotid glands was the most predictive factor (AUC: 0.72) for acute TD. The tolerance dose of 50% for the parotid glands to develop acute TD ≥ 2 during RT was 24 Gy. The Dmean of the parotid glands to the predicted 10%, 30% and 50% probabilities of long-term TD were 45, 78 and 94 Gy after 3 months and 80, 97 and 105 Gy after 6 months, respectively.
conclusionsA lower BMI was significantly associated with TD, and a significant correlation was observed between TD and quality of life (QoL). The incidence of TD is closely related to the radiation dose, and reducing the dose to the parotid glands can lower the risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.